NO20011091L - Umettede hydroksiminsyrederivater som PARP inhibitorer - Google Patents

Umettede hydroksiminsyrederivater som PARP inhibitorer

Info

Publication number
NO20011091L
NO20011091L NO20011091A NO20011091A NO20011091L NO 20011091 L NO20011091 L NO 20011091L NO 20011091 A NO20011091 A NO 20011091A NO 20011091 A NO20011091 A NO 20011091A NO 20011091 L NO20011091 L NO 20011091L
Authority
NO
Norway
Prior art keywords
acid derivatives
parp inhibitors
hydroxymic acid
treatment
unsaturated hydroxymic
Prior art date
Application number
NO20011091A
Other languages
English (en)
Other versions
NO20011091D0 (no
Inventor
Peter Literati Nagy
Balazs Suemegi
Kalman Takacs
Original Assignee
Gene Kutato Kft N
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from HU9802001A external-priority patent/HU9802001D0/hu
Priority claimed from HU9902927A external-priority patent/HUP9902927A3/hu
Application filed by Gene Kutato Kft N filed Critical Gene Kutato Kft N
Publication of NO20011091D0 publication Critical patent/NO20011091D0/no
Publication of NO20011091L publication Critical patent/NO20011091L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C251/00—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton
    • C07C251/32—Oximes
    • C07C251/50—Oximes having oxygen atoms of oxyimino groups bound to carbon atoms of substituted hydrocarbon radicals
    • C07C251/58—Oximes having oxygen atoms of oxyimino groups bound to carbon atoms of substituted hydrocarbon radicals of hydrocarbon radicals substituted by nitrogen atoms not being part of nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/04—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pyridine Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)

Abstract

Hensikten med den foreliggende oppfinnelsen består av nye umettede hydroksiminsyrederivater, fremgangsmåten for deres fremstilling og som aktive substanser så som forbindelser som inneholder farmasøytiske sammensetninger. De nye forbindelsene viser verdifulle farmasøytiske effekter, så de kan bli benyttet i behandlingen av tilstander koblet med energiunderskudd i cellen forårsaket av PARP-inhibisjon, i diabetes-komplikasjoner, i oksygenunder-skuddsstatus i hjertet og hjernen, i nevrodegenerative sykdommer, i behandlingen av autoimmune og/eller virus-sykdommer. I formel (I).
NO20011091A 1998-09-03 2001-03-02 Umettede hydroksiminsyrederivater som PARP inhibitorer NO20011091L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
HU9802001A HU9802001D0 (en) 1998-09-03 1998-09-03 New unsaturated hydroximic acid derivatives, process for producing them, and pharmaceutical compositions containing them
HU9902927A HUP9902927A3 (en) 1999-08-31 1999-08-31 New unsaturated hydroxym-acid-derivatives, process for their production and medicaments containing them
PCT/HU1999/000062 WO2000014054A1 (en) 1998-09-03 1999-09-02 Unsaturated hydroximic acid derivatives as parp inhibitors

Publications (2)

Publication Number Publication Date
NO20011091D0 NO20011091D0 (no) 2001-03-02
NO20011091L true NO20011091L (no) 2001-05-02

Family

ID=89999161

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20011091A NO20011091L (no) 1998-09-03 2001-03-02 Umettede hydroksiminsyrederivater som PARP inhibitorer

Country Status (25)

Country Link
US (1) US6500823B1 (no)
EP (1) EP1115697B1 (no)
JP (1) JP2002524439A (no)
KR (1) KR100632522B1 (no)
CN (1) CN1211353C (no)
AT (1) ATE258916T1 (no)
AU (1) AU771782B2 (no)
BR (1) BR9913425A (no)
CA (1) CA2342898A1 (no)
CZ (1) CZ2001705A3 (no)
DE (1) DE69914614T2 (no)
DK (1) DK1115697T3 (no)
ES (1) ES2215400T3 (no)
HK (1) HK1040700A1 (no)
IL (2) IL141756A0 (no)
MX (1) MXPA01002315A (no)
NO (1) NO20011091L (no)
NZ (1) NZ510933A (no)
PL (1) PL194275B1 (no)
PT (1) PT1115697E (no)
RU (1) RU2220953C2 (no)
SK (1) SK2532001A3 (no)
TR (1) TR200100645T2 (no)
UA (1) UA65635C2 (no)
WO (1) WO2000014054A1 (no)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2220753T3 (es) * 2000-03-20 2004-12-16 N-Gene Research Laboratories Inc. Derivados de amidoxina del acido propencarboxilico, procedimiento para su preparacion, y composiciones farmaceuticas que los contienen.
EP1408966B1 (en) 2001-07-17 2008-02-20 N-Gene Research Laboratories Inc. Synergistic pharmaceutical combinations for the prevention or treatment of diabetes
CN1870991A (zh) * 2003-09-04 2006-11-29 安万特药物公司 作为多聚(adp－核糖)聚合酶(parp)抑制剂的被取代的吲哚类化合物
HUP0303584A3 (en) 2003-10-30 2009-12-28 Cytrx Corp Use of a hydroximic acid halide derivative in the treatment of neurodegenerative diseases
AU2005259864A1 (en) * 2004-06-30 2006-01-12 Combinatorx, Incorporated Methods and reagents for the treatment of metabolic disorders
US20080262062A1 (en) * 2006-11-20 2008-10-23 Bipar Sciences, Inc. Method of treating diseases with parp inhibitors
US7763601B2 (en) * 2006-11-02 2010-07-27 N-Gene Research Laboratories, Inc. Prevention and treatment of obesity
WO2018022851A1 (en) 2016-07-28 2018-02-01 Mitobridge, Inc. Methods of treating acute kidney injury
KR20190107656A (ko) 2016-11-02 2019-09-20 이뮤노젠 아이엔씨 항체-약물 콘주게이트 및 parp 억제제로 병용 치료
MX2023005954A (es) 2020-11-19 2023-09-04 Zevra Denmark As Procesos para preparar citrato de arimoclomol e intermediarios del mismo.
CN113354557B (zh) * 2021-06-07 2022-06-28 大连理工大学 一种3-苯基-2-丙烯-1-酮o-正丁基肟的制备方法及应用
WO2023053008A1 (en) * 2021-09-28 2023-04-06 Kempharm Denmark A/S Oximes and their use in treatment of gba-related diseases

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4308399A (en) 1977-08-30 1981-12-29 Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara Rt. O-(3-Amino-2-hydroxy-propyl)-amidoxime derivatives, process for the preparation thereof and pharmaceutical compositions containing same
HUT54347A (en) 1989-01-10 1991-02-28 Chinoin Gyogyszer Es Vegyeszet Improved process for producing amidoximes
HU213421B (en) * 1993-04-09 1997-06-30 Egyt Gyogyszervegyeszeti Gyar New basic ethers, pharmaceutical compns. containing the said compds. and process for prepg. them
NZ313713A (en) 1995-08-02 2001-03-30 Univ Newcastle Ventures Ltd Benzimidazole-4-carboxamide derivatives useful as poly(ADP-ribose)polymerase or PARP enzyme inhibitors
DE19756236A1 (de) 1997-12-17 1999-07-01 Klinge Co Chem Pharm Fab Neue piperazinylsubstituierte Pyridylalkan-, alken- und -alkincarbonsäureamide

Also Published As

Publication number Publication date
HK1040700A1 (en) 2002-06-21
US6500823B1 (en) 2002-12-31
DE69914614D1 (de) 2004-03-11
EP1115697A1 (en) 2001-07-18
AU5753799A (en) 2000-03-27
PL194275B1 (pl) 2007-05-31
AU771782B2 (en) 2004-04-01
TR200100645T2 (tr) 2001-06-21
KR100632522B1 (ko) 2006-10-09
WO2000014054A1 (en) 2000-03-16
NO20011091D0 (no) 2001-03-02
UA65635C2 (uk) 2004-04-15
IL141756A (en) 2006-08-01
CN1322193A (zh) 2001-11-14
IL141756A0 (en) 2002-03-10
MXPA01002315A (es) 2002-05-08
CN1211353C (zh) 2005-07-20
DK1115697T3 (da) 2004-06-07
CZ2001705A3 (cs) 2001-08-15
BR9913425A (pt) 2001-11-27
JP2002524439A (ja) 2002-08-06
CA2342898A1 (en) 2000-03-16
DE69914614T2 (de) 2005-01-05
ES2215400T3 (es) 2004-10-01
ATE258916T1 (de) 2004-02-15
SK2532001A3 (en) 2001-08-06
KR20010085760A (ko) 2001-09-07
PL346547A1 (en) 2002-02-11
PT1115697E (pt) 2004-06-30
NZ510933A (en) 2003-01-31
RU2220953C2 (ru) 2004-01-10
EP1115697B1 (en) 2004-02-04

Similar Documents

Publication Publication Date Title
BR9916732A (pt) Derivados de ácido malÈnico, processo para a sua preparação, seu uso e composições farmacêuticas contendo-os (inibição da atividade do fator xa)
NO20052864L (no) Nye hydroksyindoler, deres anvendelse som fosfordiesterase 4 inhibitorer samt fremstilling av forbindelser
EA200602191A1 (ru) 5,5-дизамещённые-2-амино-4-тиазолидиноны и способ их получения, фармацевтическая композиция и способ лечения
NO994671L (no) Aryl- eller heteroarylsulfonamid-substituerte hydroksamsyrederivater, fremgangsmåte til fremstilling derav og deres anvendelse som farmasöytika
NO174202C (no) Analogifremgangsmåte for fremstilling av terapeutisk aktivt azainden-derivater
ATE411280T1 (de) Phenoxyessigsäure-derivate zur behandlung von störungen der atemwege
NO20074647L (no) 3,4 dihydro-1H-isoquinolin-2-karboksylsyre-5-ammopyridin-2-yl estere
NO20011091L (no) Umettede hydroksiminsyrederivater som PARP inhibitorer
NO20063495L (no) Kjemokine CCR5-receptormodulatorer
ES471981A1 (es) Un procedimiento para la preparacion de derivados de imida- zoquinazolina
RU97100747A (ru) Ингибиторы ферментов
SE0104340D0 (sv) New compounds
CZ76995A3 (en) Derivatives of 1-(oxoacetyl)pipridine-2-carboxylic acid, process of their preparation pharmaceutical composition containing thereof and their use
NO20060168L (no) Pyridinylkarbamater som hormonsensitive lipaseinhibitorer
ATE388951T1 (de) Dpp-iv-inhibierende purin-derivative zur behandlung von diabetes
DE502005008971D1 (de) Substituierte 1,4,8-triazaspiroä4.5 decan-2-on-verbindungen zur behandlung von fettsucht
NO20064951L (no) 1,3,4-oksadiazol-2-oner som PPAR delta-modulatorer og deres anvendelse
ATE527261T1 (de) 7-aryl-3,9-diazabicycloä3.3.1ünon-6-en-derivate und ihre verwendung als renin-inhibitoren zur behandlung von bluthochdruck, herz-kreislauf- erkrankungen und nierenkrankheiten
Sohn et al. Effects of light‐emitting diode irradiation on RANKL‐induced osteoclastogenesis
ATE451922T1 (de) Verwendung von thiazolidinon-derivaten zur behandlung von festen tumoren
MD1688F2 (en) Benzothiophene, benzofuran and indolethiazepinons, oxazepinons and diazepinons, pharmaceutical composition, method of inhibiting the leucocytes adherence to the endothelial cells for inflammatory diseases treatment and method of treatment of the mammals affected by the HIV infection
CA2370692A1 (en) Antitumor derivative of double dicarboxylic acid diaminoplatin complex, process for the preparing thereof, the pharmaceutical composition containing the same and application of the derivative
DE60221283D1 (de) Verwendung von oxindolderivaten zur behandlung von mit demenz in zusammenhang stehenden krankheiten, alzheimer-krankheit und mit glycogensynthasekinase-3 assoziierten leiden
DE602006009556D1 (de) Chinolin-derivate zur behandlung von mglur5-rezeptor-vermittelten erkrankungen
IL163951A (en) Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application